- Home
- BPMC
as 12-20-2024 4:00pm EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 5.9B | IPO Year: | 2015 |
| Target Price: | $120.79 | AVG Volume (30 days): | 667.8K |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $72.24 - $121.90 | Next Earning Date: | 02-13-2025 |
| Revenue: | $434,415,000 | Revenue Growth: | 100.93% |
| Revenue Growth (this year): | 108.09% | Revenue Growth (next year): | 39.34% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | Dec 12 '24 | Sell | $93.44 | 1,819 | $169,635.81 | 14,967 | |
| Haviland Kate | BPMC | CHIEF EXECUTIVE OFFICER | Nov 29 '24 | Sell | $96.63 | 2,353 | $227,304.36 | 150,824 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | Nov 27 '24 | Sell | $95.10 | 2,274 | $216,257.40 | 71,657 | |
| COATS LONNEL | BPMC | Director | Nov 20 '24 | Sell | $94.31 | 19,824 | $1,869,657.63 | 2,242 | |
| Albers Jeffrey W. | BPMC | Director | Nov 7 '24 | Sell | $102.00 | 5,000 | $510,000.00 | 157,557 | |
| Namouni Fouad | BPMC | PRESIDENT, R & D | Oct 3 '24 | Sell | $89.32 | 3,633 | $324,499.56 | 69,070 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire
15 days ago
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
Simply Wall St.
19 days ago
Exploring Three High Growth Tech Stocks in the United States
Zacks
23 days ago
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
MT Newswires
a month ago
Blueprint Medicines Insider Sold Shares Worth $1,869,658, According to a Recent SEC Filing
Benzinga
a month ago
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
MT Newswires
a month ago
JPMorgan Initiates Blueprint Medicines at Overweight With $126 Price Target
Simply Wall St.
2 months ago
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.